Table 2.

Primary and Secondary Outcome Measures at the 3- and 12-Month Follow-up

Usual Care (n = 59)Injection (n=60)
OutcomeBaseline3 mo12 moBaseline3 mo12 mo3 mo OR (95% CI)12 mo OR (95%CI)
EQ-5D = a quality-of-life instrument from EuroQol; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
a Fully or strongly recovered.
b Adjusted for baseline values of the outcome.
c Scored on a range from 0–10, where 0 = no pain and 10 = worst conceivable pain.
d Scored on a range from 0–100, with high values indicating more pain or lower physical functioning.
e Scored on a range from 0–1, where 0 = worst quality of life and 1 = best quality of life.
Recovered,n/N (%)a20/59 (34)33/55 (60)33/60 (55)34/56 (61)2.38 (1.14 to 5.00)1.05 (0.50 to 2.27)
Difference at 3 mo (95% CI)bDifference at 12 mo (95% CI)
Pain at rest, mean (SD)c5.3 (2.2)3.7 (2.5)2.3 (2.3)5.1 (2.2)2.5 (2.5)2.1 (2.5)1.18 (0.31 to 2.05)0.14 (−0.75 to 1.04)
Pain with activity, mean (SD)c6.6 (2.60)4.8 (2.8)3.2 (2.9)6.7 (1.9)3.6 (2.8)2.8 (2.8)1.30 (0.32 to 2.29)0.45 (−0.55 to 1.46)
Secondary outcomes
    WOMAC pain, mean (SD)d52.4 (19.1)37.6 (22.7)122.9 (22.8)48.8 (16.1)23.6 (21.3)18 (19.6)12.40 (4.86 to 19.93)2.67 (−4.98 to 10.32)
    WOMAC function, mean (SD)d49.2 (19.6)34.2 (21.3)21.7 (22.7)43.9 (17.0)21.3 (19.3)17.4 (19.6)11.36 (4.01 to 18.70)1.01 (−6.37 to 8.39)
    EQ-5D, mean (SD)e0.72 (0.2)0.79 (0.17)0.85 (0.17)0.74 (0.2)0.81 (0.2)0.82 (0.2)−0.02 (−0.08 to 0.04)−0.004 (−0.05 to 0.06)